Referring Physicians – the following is technical details for your information and in the event you have patients you feel might be appropriate to refer. Please contact the person listed for the specific trial or study, or the lead investigator.
To assess the safety and effectiveness of the investigational drug ORACEA®, to determine if it can slow the progression of geographic atrophy in your study eye in participants who have geographic atrophy secondary to non-exudative age-related macular degeneration (dry AMD).
6 study visits over a 25-month period with additional testing
Contact: Carly Satsuma, 617-636-5489
Principal Investigator: Johanna M. Seddon, MD., ScM
Definition: AMD is a retinal degenerative disease that causes a progressive loss of central vision. AMD is the most common cause of vision loss in individuals age 60 years and older. Juvenile onset forms of macular degeneration, like Stargardt and Best disease, also can cause severe loss of vision.
Target Population: Individuals with macular degeneration (wet or dry) and spouses, siblings and adult children (with or without AMD), including age-related and juvenile onset forms of macular degeneration.
Duration: On-going since 1989.
Purpose: The purpose of this research study is to determine the causes of macular degeneration so we can prevent it and find better treatments. We will continue to identify genes and environmental determinants of macular degeneration. Eligible study participants will have an eye exam and blood draw. Participants will also complete questionnaires on diet and risk factors.
YOU DO NOT NEED TO LIVE IN THE BOSTON AREA TO PARTICIPATE.
Contact: Project Manager,
Ophthalmic Epidemiology and Genetics Service
New England Eye Center
Tufts Medical Center
800 Washington Street #450
Boston, MA 02111
617-636-9000 or toll free: 800-219-9157
Inclusion Criteria: Dry and Wet AMD, Stargardt, Best, High Myopia, other Macular Dystrophies
Age Range: Any, and normal patients age 65+
Payment: None, but ***Patients do not need to come into Boston to participate***
Contact: Dr. Seddon’s Study Staff: 6-9000
Sponsor: Johnson & Johnson
Inclusion Criteria: Age-related macular degeneration with geographic atrophy, BCVA of 20/80-20/800, refraction of +10.00D to -8.00D, up to 4.00D of astigmatism
Study Length and Visits: 2 visits within 6 months
Age Range: 55-90
Payment: $100 on completion of 2 visits, Transportation up to an additional $60
Contact: Mildred Commodore, 617-636-1051, Carly Satsuma, 617-636-5489
Inclusion Criteria: AMD, No contraindications to MRI Scanning (electrical implants, ferromagnetic implants or objects, weight > 350 lbs, women of childbearing age seeking to become pregnant or may be pregnant, pre-existing medical condition likely to develop seizures or claustrophobic reactions, and greater than normal potential for cardiac arrest)
Study Length and Visits: 1 visit
Age Range: 18+ years
Payment: $150, ***Transportation Provided***
Contact: Carly Satsuma, 617-636-5489, Mildred Commodore, 617-636-1051
Sponsor: Second Sight
New England Eye Center is now screening patients for the Argus II Retinal Prosthesis System. This is an implant for the eye that can partially restore vision for patients who are blind from Retinitis Pigmentosa.
The Argus II is an electrode implant that receives signals from an external video processing unit and is based on what the patient sees through a video camera housed in special glasses. The video is processed and signals are sent wirelessly to the implant to stimulate the retinal cells and transmit visual information to the brain, creating the perception of patterns of light. Over time, users learn how to interpret these visual patterns as objects and shapes.
While the Argus II System has already been approved by the FDA as a humanitarian use device, New England Eye Center MDs will be studying the long-term effects of this device.
Contact: Carly Satsuma, 617-636-5489
Group #1: Age 4-10 years, untreated or minimally treated amblyopia with possible need for patching/atropine, BCVA in amblyopic eye 20/30 to 20/80, 20/30 or better in fellow eye, no previous intraocular or refractive surgery, no coexisting ocular, neurological or systemic disease that could impact visual acuity assessment Group #2: Age 4-15 years, amblyopia, one or more other eye conditions with amblyopic component, BCVA in amblyopic eye 20/30 to 20/80, 20/30 or better in fellow eye
Risk: Minimal, including possible temporary headaches, double vision, eye strain timeframe
Benefit: Alternative treatment to patching/atropine, potential improvement in vision Study Length and Visits: 16 weeks, 4 visits (5 visits including enrollment visit)
Contact: Principal Investigator Dr. Vicki Chen, Co-Investigators Dr. Catherine Choi, Dr. Nicole Quinn, Dr. Mitchell Strominger, Dr. Sylvia Yoo, or Shelley Klein: 617-636-6769
Risk:Minimal, including possible temporary eye strain and photophobia from dilating drops
Benefit:Enhance understanding of anatomic differences associated with amblyopia and assess whether structural changes occur with appropriate treatment
Study Length and Visits: 4 visits total over course of 1 year, at 3 month intervals
Payment: None currently (pending additional funding)
Contact: Principal Investigator Dr. Catherine Choi, Co-Investigators Dr. Vicki Chen, Dr. Nicole Quinn, Dr. David Reese, Dr. Mitchell Strominger, Dr. Sylvia Yoo, or Shelley Klein: 617-636-6769
Study Length and Visits: 1 to 2 study visits
Age Range: > 18 years old
Payment: $50 for participation
Contact: Mildred Commodore, 617-636-1051 or Carly Satsuma, 617-636-5489
No eye disease/infection/surgery within the past year, No dry eye symptoms (e.g. itching, burning, light sensitivity), No history of DED or Diabetes, General good health, Does not wear contact lenses or currently use eye medications
Study Length and Visits: One visit
Age Range: 40+ years old
Payment: $50 for participation in study
Contact:Carly Satsuma, 617-636-5489